Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test

Natera, a leading innovator in prenatal genetic testing, today announced the initiation of a distribution partnership with ProPath, a wholly physician-owned provider of pathology services to clinicians and medical facilities in the United States, for its Panorama™ non-invasive prenatal screening test (NIPT).

Panorama has been validated globally in multiple clinical trials and is the only NIPT to consistently demonstrate high sensitivity and specificity for all major aneuploidies beyond Down syndrome, including trisomy 13 (Patau syndrome), trisomy18 (Edwards syndrome), triploidy and sex chromosome abnormalities. Panorama is now also able to screen for microdeletions, such as the 22q11.2 deletion (DiGeorge syndrome), which is caused by a small deletion on chromosome 22. DiGeorge results in a range of developmental problems, such as heart disease, cleft palate, learning disabilities as well as weak immune systems. The microdeletions screened for by Panorama occur with a combined incidence of approximately 1 in every 1,000 births, occur equally across all maternal ages, and for younger mothers are more prevalent than Down syndrome.

"We have seen increasing demand for non-invasive prenatal testing, and we are proud to offer Panorama with its ability to more accurately and comprehensively screen for abnormalities than conventional tests," said Kenneth E. Youens, M.D., director of women's health for ProPath. "We look forward to rolling out this test quickly and making it available to our medical facilities and clinicians nationwide."

Matthew Rabinowitz, Ph.D., chief executive officer of Natera, said, "ProPath is an excellent partner for us, with a wide network in the United States as we continue to expand access to Panorama. We look forward to working with ProPath to reach more patients as we continue to investigate all potential applications for this promising technology."

Panorama uses a simple blood draw from the mother, examines cell-free DNA found in maternal blood originating from both mother and fetus, and can be performed within the first trimester of pregnancy, as early as nine weeks, without any risk to the fetus. Panorama's technology analyzes, in a single reaction, 19,500 single nucleotide polymorphisms (SNPs), which are the most informative portions of an individual's DNA. It utilizes the NATUS [Next-generation Aneuploidy Testing Using SNPs] algorithm, an advanced version of Natera's proprietary informatics. In published clinical trials, Panorama has demonstrated a sensitivity of greater than 99% for trisomy 21, trisomy 18 and trisomy 13, 92% for monosomy X, and a less than 0.1% false positive rate for all syndromes tested.

Source:

Natera Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Natera. (2019, June 19). Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test. News-Medical. Retrieved on March 08, 2021 from https://www.news-medical.net/news/20140212/Natera-initiates-distribution-partnership-with-ProPath-for-Panorama-non-invasive-prenatal-screening-test.aspx.

  • MLA

    Natera. "Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test". News-Medical. 08 March 2021. <https://www.news-medical.net/news/20140212/Natera-initiates-distribution-partnership-with-ProPath-for-Panorama-non-invasive-prenatal-screening-test.aspx>.

  • Chicago

    Natera. "Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test". News-Medical. https://www.news-medical.net/news/20140212/Natera-initiates-distribution-partnership-with-ProPath-for-Panorama-non-invasive-prenatal-screening-test.aspx. (accessed March 08, 2021).

  • Harvard

    Natera. 2019. Natera initiates distribution partnership with ProPath for Panorama non-invasive prenatal screening test. News-Medical, viewed 08 March 2021, https://www.news-medical.net/news/20140212/Natera-initiates-distribution-partnership-with-ProPath-for-Panorama-non-invasive-prenatal-screening-test.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Panorama SNP-based non-invasive prenatal test can detect complete molar pregnancy